Video

What the re:Vive 2.0 platform may mean for the future of vision diagnostics

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
© 2025 MJH Life Sciences

All rights reserved.